DUBLIN–(BUSINESS WIRE)–The “Global
Friedreich’s Ataxia Clinical Trial Pipeline Highlights – 2019”
report has been added to ResearchAndMarkets.com’s
offering.
Friedreich’s Ataxia Pipeline Highlights – 2019, provides most up-to-date
information on key pipeline products in the global Friedreich’s Ataxia
market. It covers emerging therapies for Friedreich’s Ataxia in active
clinical development stages including early and late stage clinical
trials. The pipeline data presented in this report helps executives for
tracking competition, identifying partners, evaluating opportunities,
formulating business development strategies, and executing in-licensing
and out-licensing deals.
Clinical Trial Stages:
The report provides Friedreich’s Ataxia pipeline products by clinical
trial stages including both early and late stage development – phase 3
clinical trials, phase 2 clinical trials, phase 1 clinical trials,
preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Friedreich’s Ataxia pipeline products by their
dominant mechanism of action/drug class. This helps executives
categorize products based on their drug class and also assess the
strengths and weaknesses of compounds.
Company:
The report provides Friedreich’s Ataxia pipeline products by the company.
Short-term Launch Highlights:
Find out which Friedreich’s Ataxia pipeline products will be launched in
the US and Ex-US till 2024.
Key Topics Covered:
1. Friedreich’s Ataxia Pipeline by Stages
2. Friedreich’s Ataxia Phase 3 Clinical Trial Insights
3. Friedreich’s Ataxia Phase 2 Clinical Trial Insights
4. Friedreich’s Ataxia Phase 1 Clinical Trial Insights
5. Friedreich’s Ataxia Preclinical Research Insights
6. Friedreich’s Ataxia Discovery Stage Insights
7. Appendix
8. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/67sq72
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs, Clinical
Trials